FG urged to repair pharma manufacturing bottlenecks

Stakeholders have referred to as on the Federal Authorities to prioritise easing native pharmaceutical producers’ challenges, together with a harsh commerce and regulatory surroundings, because it seeks to draw overseas funding into the sector.

In a phone interview, the previous president of the Pharmaceutical Society of Nigeria, Olumide Akintayo, confused that an enabling enterprise surroundings is essential for the business to thrive.

“The very first duty of presidency is to ensure the safety of the lives of individuals and the general public. We wish to see that the federal government creates an enabling surroundings for the residents, making issues conducive to working companies, whether or not it’s pharma or some other sector,” Akintayo mentioned.

His feedback come after the Federal Minister of Trade, Commerce and Funding, Dr. Jumoke Oduwole, disclosed in a press interview on the World Financial Discussion board in Davos that she was working with the Minister of Health, Muhammad Pate, to convey an unnamed overseas healthcare producer into Nigeria as a part of efforts to spice up pharmaceutical manufacturing.

Whereas acknowledging the advantages of overseas funding, Akintayo insisted that native producers should not be left to wrestle beneath burdensome tariffs and excessive operational prices.

“We have already got a conglomerate of Indian pharmaceutical factories. I’m positive you’ve heard of Jawa Prescription drugs; they got here up with the beta-lactam, principally an Indian firm,” Jawa continued. “However the precept is straightforward: whether or not overseas or indigenous producers, it does our financial system quite a lot of good when individuals produce issues round there.

“In fact, it’s significantly better if they’re Nigerian producers due to the status they bring about and the potential hub for prescribed drugs it creates.”

The pharmacist questioned the effectiveness of President Bola Tinubu’s government order, signed in June 2024, waiving responsibility funds on the importation of sure pharmaceutical inputs.

His remarks: “President Tinubu signed an government order virtually one 12 months in the past, and the primary query you ask your self is, what has modified between that point and now? If nothing has modified, then what are the basics? Why is it that you simply don’t have an enchancment? Why has it not impacted drug costs?

He decried extreme tariffs, exorbitant registration charges, and excessive prices, which proceed to stifle native pharmaceutical corporations at completely different ports.

 “How will we run our enterprise on the varied factors of entry? What’s the distinction between bringing in these merchandise by way of the Seme level or the purpose of entry in Ghana? We’ve got to have a look at all of those variables. And then you definately see why now we have issues.

“Are we doing sufficient to encourage native manufacturing of excipients? One of the crucial widespread excipients within the pharma business is pharmaceutical-grade starch. We’re reputed to be the best producer of yams, but we import pharmaceutical-grade starch, however we’re not producing it even once we produce the best quantity of cassava starch.

He’s additionally apprehensive that there has not been a lot progress in checking the overreach of safety forces.

“Discover out what the expertise of exporters is like,” the pharmacist submitted. “You can not take a container that you’re exporting yam, wheat, or something by way of the port in Apapa with out policemen assigned to police posts amassing cash in a number of thousands and thousands of naira relying on the worth of what you are attempting to ship. We have to return to the fundamentals.”

Akintayo criticised regulatory businesses for prioritising internally generated income over public well being, querying, “Why are regulatory businesses within the pharma sector among the many high three earners of cash for the federal government? So, you prioritise IGR over the well being of the individuals? Drug costs are exorbitant, but authorities businesses introduce new insurance policies that power pharma corporations to alter product labels, main to a different spherical of expensive funding.

Equally, the President of the Lagos Chamber of Commerce and Trade, Gabriel Idahosa, in a phone interview, referred to as for the pressing implementation of the pharmaceutical inputs duty-free waiver, attributing the delay to poor coordination amongst authorities businesses.

“The delay within the implementation of the pharmaceutical inputs duty-free waiver is a matter of presidency businesses not coordinating effectively amongst themselves. The implementation of the waiver is one thing that flows from the Central Financial institution to the business banks that fund these transactions. The federal government is supposed to coordinate,” Idahosa acknowledged.

He additionally clarified misconceptions in regards to the departure of pharmaceutical multinationals from Nigeria.

“Even earlier than the pharmaceutical multinationals left, Nigeria was not producing as much as 20 to 30 per cent of all the drugs wanted as a rustic. Once they left, they didn’t carry their factories with them. These factories are nonetheless right here in Lagos and each different place they had been working,” he defined.

Idahosa affirmed that the Minister of FMITI, Oduwole, in her assertion in Davos, emphasised the federal government’s medical industrialisation coverage, which he interpreted as taking management to make Nigeria a hub for medical manufacturing, together with vaccines.

“Nigeria should embark on an enormous programme of medical industrialisation to satisfy our medical wants and that of our neighbours who can’t afford high-end medical industries,” he added.

The stakeholders maintained that whereas overseas funding is welcome, addressing native business challenges stays the important thing to sustaining the native pharmaceutical sector.